Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537516 | 0.89 | TDP1 (0.46) | CARM1PRMT6TDP1DRD2DRD4 | |
| SCHEMBL1990800 | 0.86 | TDP1 (0.57) | CARM1PRMT6TDP1DRD2DRD4 | |
| SCHEMBL10533845 | 0.82 | PARP15 (0.56) | CARM1PRMT6TDP1 | |
| SCHEMBL7034688 | 0.81 | SIGMAR1 (0.45) | DRD2DRD4 | |
| SCHEMBL7688951 | 0.81 | TEAD1 (0.50) | — | |
| SCHEMBL8356592 | 0.80 | PARP15 (0.57) | CARM1PRMT6TDP1 | |
| SCHEMBL5525582 | 0.79 | CARM1 (0.48) | CARM1PRMT6TDP1 | |
| SCHEMBL12901467 | 0.79 | CARM1 (0.48) | CARM1PRMT6TDP1DRD2DRD4 | |
| SCHEMBL3154460 | 0.79 | TDP1 (0.43) | CARM1PRMT6TDP1DRD2DRD4 | |
| SCHEMBL31268338 | 0.78 | PARP15 (0.56) | CARM1PRMT6TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0625514-B1 | 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1999-08-25 | — | — | EP | claimed |
| US-5420130-A | Adrenergic blocking agents | SYNTHELABO (FR) | 1995-05-30 | — | — | US | claimed |
| JP-6329645-A | — | — | None | — | — | JP | disclosed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
| EP-0808303-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996024582-A1 | 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST | ZENECA LIMITED (GB) | 1996-08-15 | — | — | WO | disclosed |
| US-5466706-A | Compounds for hypnotics, anxiety or anticonvulsants | SYNTHELABO (FR) | 1995-11-14 | — | — | US | disclosed |
| CN-1104637-A | Derivative of 2-aminopyrazine-5-carboxamide, preparation and pharmaceutical use of same | SYNTHELABO (FR) | 1995-07-05 | — | — | CN | disclosed |
| US-5420130-A | Adrenergic blocking agents | SYNTHELABO (FR) | 1995-05-30 | — | — | US | disclosed |
| US-5420130-A | Adrenergic blocking agents | SYNTHELABO (FR) | 1995-05-30 | — | — | US | disclosed |
| JP-H06329645-A | 1-AMINOPYRAZINE-5-CARBOXAMIDE DERIVATIVE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | SYNTHELABO SA | 1994-11-29 | — | — | JP | disclosed |
| EP-0625514-A1 | 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1994-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | CARM1 3558/4885PRMT6 3503/4885TDP1 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.